CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Zydus Pharmaceuticals (USA) Inc recalls Bromocriptine Mesylate Capsules

Read the official FDA notice

Published
26 Nov 2025
Units affected
36,624 bottles
Agency
FDA
Country
United States

The hazard

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06

Brand / company
Zydus Pharmaceuticals (USA) Inc
Codes / lots
Lot #: M313934, M313935, M315615, Exp. Date Nov 2025; M316809 , Exp. Date Dec-25; M405765, M405763, M405764, Exp. Date Apr-26; M414999, M414241, M414307, M414305, Exp. Date Oct-26
Distribution
Nationwide in the USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 26 Nov 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.